← Back to Search

Tyrosine Kinase Inhibitor

Sitravatinib Combination Therapy for Solid Cancers

Phase 2 & 3
Waitlist Available
Research Sponsored by Mirati Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug, sitravatinib, to see if it works better than other cancer drugs currently available.

Who is the study for?
This trial is for patients already benefiting from Sitravatinib alone or with other cancer drugs in a previous study, without severe side effects or another life-threatening illness. The doctor must believe continuing treatment is good for the patient.Check my eligibility
What is being tested?
The study tests if Sitravatinib, on its own or combined with drugs like Ipilimumab, Nivolumab, Pembrolizumab, and Enfortumab Vedotin-Ejfv helps advanced solid tumors. It's for those who saw benefits in an earlier Mirati-sponsored trial.See study design
What are the potential side effects?
Possible side effects include immune system reactions that can affect organs, infusion-related symptoms, fatigue, skin issues and potential complications from combining multiple treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of subjects experiencing treatment-related AEs.
Secondary outcome measures
Time to clinical or radiographic progression on study.

Side effects data

From 2023 Phase 2 trial • 25 Patients • NCT03680521
86%
Hypertension
71%
Dysphonia
57%
Headache
43%
Fatigue
43%
Constipation
43%
Lipase increased
43%
Oral dysaesthesia
29%
Blood thyroid stimulating hormone increased
29%
Hypothyroidism
29%
Hypotension
29%
Myalgia
29%
Diarrhoea
29%
Urinary tract infection
29%
Vomiting
29%
Pain
29%
Amylase increased
14%
Arthralgia
14%
Cough
14%
Abdominal pain
14%
Acute respiratory failure
14%
Weight decreased
14%
Nasal congestion
14%
Epistaxis
14%
Flank pain
14%
Alanine aminotransferase increased
14%
Hyperuricaemia
14%
Memory impairment
14%
Musculoskeletal pain
14%
Night sweats
14%
Urinary retention
14%
Nausea
14%
Rash
14%
Decreased appetite
14%
Dizziness
14%
Haematuria
14%
Nail discolouration
14%
Hypoglycaemia
14%
Oral herpes
14%
Pain in jaw
14%
Pneumonitis
14%
Procedural pain
14%
Pyrexia
14%
Rhinitis allergic
14%
Rhinorrhoea
14%
Sinus congestion
14%
Somnolence
14%
Thrombocytopenia
14%
Tinnitus
14%
Tooth abscess
14%
Herpes zoster
14%
Chills
14%
Urosepsis
14%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sitravatinib 120 mg
Sitravatinib 80 mg

Trial Design

1Treatment groups
Experimental Treatment
Group I: Phase 2/3: Open label extension of parent studyExperimental Treatment5 Interventions
The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ipilimumab
2014
Completed Phase 3
~2620
Sitravatinib
2021
Completed Phase 2
~700
Nivolumab
2014
Completed Phase 3
~4750
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
70 Previous Clinical Trials
8,055 Total Patients Enrolled
Ronald Shazer, MDStudy DirectorMirati Therapeutics Inc.
1 Previous Clinical Trials
370 Total Patients Enrolled

Media Library

Sitravatinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04887870 — Phase 2 & 3
Solid Cancers Research Study Groups: Phase 2/3: Open label extension of parent study
Solid Cancers Clinical Trial 2023: Sitravatinib Highlights & Side Effects. Trial Name: NCT04887870 — Phase 2 & 3
Sitravatinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04887870 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants will this research include?

"As of 8/23/2022, this particular clinical trial is no longer recruiting patients. The initial posting was on 6/30/2021. However, there are many other trials enrolling cancer patients (2458) and Sitravatinib trials (1763)."

Answered by AI

What are the main health concerns that Sitravatinib addresses?

"Sitravatinib is commonly used to treat unresectable melanoma. Other conditions that this medication can help ameliorate include microsatellite instability high, squamous cell carcinoma, and high risk of recurrence."

Answered by AI

Does Sitravatinib have a history of being studied in other medical trials?

"Sitravatinib is being trialed in 1763 studies, 206 of which are Phase 3 clinical trials. The primary location for these Sitravatinib trials is Houston, Texas; however, there are 76481 locations running similar studies."

Answered by AI

In how many different countries is this trial taking place?

"Patients are being enrolled for this trial at New york Oncology Hematology, P.C., Rocky Mountain Cancer Centers, Dana-Farber Cancer Institute, and 12 other locations across the nation."

Answered by AI

Is this experiment still looking for participants?

"Unfortunately, this particular clinical trial is not looking for new participants at the moment. The posting date was June 30th 2021 with the most recent update on August 23rd 2022. Although this study has wrapped up recruitment, there are 4221 other ongoing trials that may be of interest."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
2021. "Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04887870.
~53 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top